I wonder if the change in the listing status requires a filing? No matter, though. I think Leo gave us a heads-up yesterday very similar to the one he delivered in August. For anyone following along it should be obvious that the Brilacidin report will be very good. Big Pharma testing B for prophylactic use? Fantastic news!
Cohort 10? Would anyone have guessed as much two years ago? Thankfully we have Brila to carry the load while we wait for Kevetrin, which is obviously meeting or exceeding expectations.